i. executive summary 5 ii. study goal and objectives 13
TRANSCRIPT
1
Table of Contents
Page
I. Executive Summary 5II. Study Goal and Objectives 13III. Respondent Demographics 15IV. Use and Satisfaction 22V. Selection Criteria and Perceptions 30VI. Company Profiles 39
2
Preface
We have been conducting voice of the customer research in the eClinical platform space for more than a decade, watching customers migrate from early piecemeal solutions offered by larger clinical CROs to early standards such as Oracle Clinical. Enter Medidata with its Rave EDC and Clinical Cloud platform, which won over customers with a pure-play eClinical platform that became the de-facto market leader. Since then, several other eClinical platform providers have entered the space with several making significant inroads to the point that they are are challenging the market leader.
Given that we had not undertaken a large, market survey of customer perceptions of the leading eClinical providers in several years, we felt the timing was right to take a fresh look. We were anxious to see if Medidata was still at the forefront of customer perceptions for market leadership, vendor performance and satisfaction, or if other strong market competitors, like Veeva, IQVIA or Covance, had overtaken the leader with their solutions.
Upon digging into the data an interesting story emerges. The established market leader, while still firmly perceived to be as such, has a few clear “holes in its armor”. One vendor, in particular, is offering a platform solution that is resonating with customers through its intuitiveness and ease of use, to the point that we will be watching this market closely to see if a “passing of the market leadership torch” happens in the future.
The following report details customer perceptions of the leading eClinical platforms and providers across a multitude of vendor selection, performance and satisfaction metrics. We have analyzed the data from which the implications are clear. The Pharma industry is looking for eClinical platforms that guarantee the quality and integrity of its data while improving overall efficiency. The eClinical platform that delivers this to the market will be best positioned to succeed.
-Life Science Strategy Group, LLC
3
N=100
• More than 70 unique biopharmaceutical companies are represented by the research sample.
N=100
Respondent Demographics
Source: Life Science Strategy Group, LLC
Q. Where are you located?Q. Which BEST describes the type of company that you currently work for?Q. What activities are part of your current role as it relates to the decision-making process for procuring and or selecting an external provider for an eClinical Platform solution?
N=100
Location 18%
82%
0% 50% 100%% of Respondents
Pharma/Biotech Company
Size 29%
34%
37%
0% 10% 20% 30% 40%% of Respondents
North America
Europe
Mid-Size($300M to $1B R&D Spend)
Large (>$1B R&D Spend)
Small(<$300M R&D Spend)
78%19% 3%
0%
20%
40%
60%
80%
100%
% o
f Res
pond
ents
Part of a team or committee
Final decision maker
End user/Daily interaction with the external provider
Decision Influence
(% of Respondents)
(% of Respondents)
4
35% 63% 87% 85% 40%0%
20%40%60%80%
100%
% o
f Res
pond
ents
4% 16% 26% 54%
0%
20%
40%
60%
% o
f Res
pond
ents
N=100
Source: Life Science Strategy Group, LLC
Q. How many years combined have you been in your current and related roles?Q. Within what Phase(s) of drug development are you actively involved? Please select all that apply.Q. Please indicate your position level or equivalent.
Respondent Demographics
N=100
1 to 3 yearsYears of
Experience
10%16%20%54%
0% 10% 20% 30% 40% 50% 60%% of Respondents
C-Suite
Vice PresidentSenior Director/Director/
Associate Director
PositionLevel
Senior Manager/ Manager/Associate Manager
4 to 7 years
8 to 15 years
More than 15 years
N=100
PreclinicalDrug
Discovery
Early Clinical(Phase I/IIa)
Phase(s) of Development Involvement
Post-approval/ Commercial
Late Clinical (Phase IIb/III)
5
N=100
Source: Life Science Strategy Group, LLCQ. What best describes your role in clinical development? Please select all that apply.
Respondent Demographics
Role in Clinical Development
4%
8%
11%
12%
20%
20%
20%
25%
35%
35%
39%
56%
68%
0% 20% 40% 60% 80%
Other*
Commercial
IT/Technology
Principal Investigator
Biostatistics/Data Science/Analytics
Medical Affairs/Medical
Regulatory Affairs
Corporate Management/C-Suite
Trial Management
Sourcing/Procurement
Program Lead/Manager
Clinical Operations
Research and Development
% of Respondents
Other* includes: Data manager, QA, Systems and processes, Quality
6
72%10%
18%
0%
20%
40%
60%
80%%
of R
espo
nden
ts
N=100
Source: Life Science Strategy Group, LLC
Q. What best describes your company’s experience with eClinical platforms?Q. What best describes your interaction with an eClinical platform/provider?
Respondent Demographics
N=100
eClinical platform being considered
eClinical platform currently in use
eClinical platform in implementation stageCompany
Experience with eClinical Platforms
21%
36%
43%
0% 10% 20% 30% 40% 50%% of Respondents
Involved in the purchasing decision, but not day-to-day use of an eClinical platform
Interaction with eClinical
Platform/Provider
Actively use eClinical platform(s) to manage clinical trials/programs
Manage/Implement clinical trial technologies
7
40% 40%
34%
28%25%
22%19%
17%
11% 10%7% 6% 5%
17%15%
20%
26%24%
27%
18%
26%
21%18%
15%
20%
8%
21%23%
26% 27%31%
34% 35%
27%
32%
37%
30% 30% 31%
13%16%
11% 12%16%
11%
17%21% 21%
25%22%
27%
11%9%
6%9%
7%4%
6%
11%9%
15%
10%
26%
17%
45%
0%
10%
20%
30%
40%
50%
% o
f Res
pond
ents
Currently using Used in the past 12-18 months, but NOT using todayFamiliar with and currently or previously considered, but never used Familiar with but never used or consideredNot aware of/Not familiar N=100
Source: Life Science Strategy Group, LLCQ. What best describes your status with each of the following eClinical platform providers/solutions? Please indicate for each provider.
Respondent Demographics
Status with eClinical Platform Providers/Solutions
8Source: Life Science Strategy Group, LLC
Companies/eClinical Platforms Included in the Analysis and Profiled
• Almac Clinical Technologies• BioClinica Cloud• Covance Xcellerate• Emmes Advantage eClinical Suite• IBM Clinical Development• ICON Flex Advantage• IQVIA Infosario• Medidata Rave Clinical Cloud• Oracle Platform and Clinical One• Parexel Perceptive Cloud• PPD CTMS• PRA Health Prism eClinical Solution• Veeva Vault Clinical
9
Top eClinical platforms increase users’ productivity while providing a consistent user experience which allows faster, more efficient clinical trials. eClinical platforms are more attractive if they help companies reduce internal effort.
Source: Life Science Strategy Group, LLCQ. What are the top benefits or value propositions offered by an eClinical platform? Please select the top-3 options.
Top Benefits/Value Propositions Offered by an eClinical Platform
53%47% 44%
39%35% 33%
24% 23%
2%0%
10%
20%
30%
40%
50%
60%
70%
Increasinguser
productivity
Providing aconsistent
userexperiencewith cross-
productworkflows
Earlier trialinitiation andfaster patientenrollment
Streamliningissue andquestionresolution
Reducinglong-term
cost
Expeditinggo/no-godecisionmaking
Preventingoverextension
of internalresources
Regulatorymandates
Other*
% o
f Res
pond
ents
Other* includes: Real time insights for sponsor into study status, Ability to assure more timely database lock on study completion
N=100
Sample Pages
10Source: Life Science Strategy Group, LLC
Q. What percent of your/your company’s clinical trials currently utilize each of the following eClinical platforms/providers as the primary solution?
eClinical Platform Share of Voice
YYY share of voice leads other providers in clinical trial utilization, followed closely by A, B and C.
1%
1%
2%
2%
4%
6%
7%
8%
8%
14%
14%
15%
18%
0% 5% 10% 15% 20%
Share of Voice N=100Note: Share of voice calculation involves percent utilization for all vendors from all respondents averaged across the full respondent sample.
Sam
ple
Page
s
11
12%12%
14%14%15%16%
21%23%
31%32%
34%34%
38%40%40%41%41%42%
0% 10% 20% 30% 40% 50%
Customer service/responsiveness/accessibilityPlatform performance/speed
Reputation of the eClinical platform providerCloud capabilities (e.g., access and administration)
Vendor's therapeutic/disease area expertiseInnovation (e.g., AI and machine learning)
Customizability/flexibilityPast experience with the eClinical platform provider
Speed and ease of implementationIntegration with existing/multiple eClinical systems
Ease of use/intuitiveRegulatory compliance
Data analytics, visualization, and reportingCost
Real-time access to dataReliability
Data securityData integrity/validation
Top Criteria Evaluated when Selecting an eClinical Platform
Top criteria evaluated when selecting an eClinical platform relate X, Y and Z.
Source: Life Science Strategy Group, LLCQ. What are the top-5 criteria evaluated when selecting an eClinical platform solution?
N=100
% of Respondents
Top criteria for mid-sized pharma
Top criteria for small pharma
Large (49%), mid-sized (28%) vs. small (7%)
Segmentation Differences
Small (45%) vs. large (22%)
Small (52%) vs. large (32%)
Sample Pages
12
Data integrity/validation
Data security
Real-time access to data
Data analytics, visualization, and reporting
Respondents perceive Veeva Vault Clinical as the top platform across several attributes, including data security, ease of use, regulatory compliance, and cloud capabilities.
Source: Life Science Strategy Group, LLC
Deep Dive Comparison – Platform Selection Criteria vs Perceived Vendor Performance
Data Quality, Access, & Analytics
Ease of use/intuitive
Speed and ease of implementation
Platform performance/speed
Platform Performance
& Ease of Use
Reliability
Regulatory compliance
Integration with eClinical systems
Customizability/flexibility
Innovation (e.g., AI and machine learning)
Cloud capabilities
Platform Capabilities
& Integration
Past experience w/eClinical platform provider
Vendor's therapeutic/disease area expertise
Reputation of the eClinical platform provider
Customer service/responsiveness/accessibility
Vendor Reputation & Expertise
Increasing Degree of High Satisfaction*±
*Top 2 Scores (% of respondents with a score of 7 and 6)±Sample sizes vary per attribute and some may be directional
Sample Pages
Sample Pages
Sample Pages
13Source: Life Science Strategy Group, LLC
Company ProfileCompany X
Platform Strengths
BrandIndustry
Avg.Advocacyǂ (NPS) -29% -38%
Repeat Business* 36% 28%
Prefer* 42%▲ 30%
Consider* 44% 32%
Use (Current + Recent) 55% 40%
Unaided Awareness 37%▲ 14%
Aided Awareness 94% 87%
Platform Weaknesses
Performance on Important Platform Selection Criteria±Top 2 Scores*
Brand Performance% of Respondents
28% of respondents perceive XXX as the market leader
n=55†N=100
Perception as Market Leader
n=78
ⱡ Net Promoter Score*Top 2 Scores (% of respondents with a score of 7 and 6)▲Top performance among all platforms±Cumulation of various attributes; sample sizes vary per attribute
†Includes respondents currently using or recently used platform
N=1
00
Share of Voice: 18%
35%28%
63%
36%
16%31% 25%
36%30%
19%
Data Quality,Access, &Analytics
PlatformPeformance
& Ease of Use
PlatformCapabilities &
Integration
VendorReputation &
Expertise
Cost
Sample Pages
Sample Pages